In a Cochrane meta-analysis of 152 studies investigating more than 100,000 nose and throat samples and 20 brands of COVID 19 tests, only the LumiraDx assay exceeded the WHO’s desirable sensitivity target of 90 per cent.
Used at point of care, LumiraDx SARS-CoV-2 Ag Test verifies COVID-19 infection in under 12 minutes.
The test ensures that a patient can rapidly begin treatment and take precautions to prevent the spread of infection.
The tests are run on a proprietary Platform that uses an advanced, actively-controlled microfluidic technology that separates it from the majority of the lateral flow tests featured in the review—providing fast, accurate, comprehensive diagnostic data at the point of need.
The Cochrane Review concluded:
“Assays that meet appropriate performance standards, such as those set by WHO, could replace laboratory‐based RT‐PCR when immediate decisions about patient care must be made, or where RT‐PCR cannot be delivered in a timely manner.”
Next-generation point of care diagnostics company LumiraDx is transforming community-based healthcare.
The company’s portable and lab comparable point of care diagnostic platform supports a broad menu of tests, with 30 either on the market or in development, spanning infectious diseases, cardiovascular diseases, diabetes and coagulation disorders.
More information on LumiraDx is available at www.lumiradx.com